Moxifloxacin, the main dosage forms are tablets and injections. This product has good antibacterial activity against Gram-negative bacteria, Gram-positive bacteria, Mycoplasma, Chlamydia and myelitis virus. This product is well absorbed orally and is not susceptible to drug resistance. Clinically used to treat respiratory infections, reproductive system infections, skin and soft tissue infections, etc.
Moxifloxacin is a synthetic quinolone antibacterial and is a relatively new synthetic antibacterial. It has the advantages of strong antibacterial property, wide antibacterial spectrum, low resistance to drug resistance, effective antibiotics, long half-life and less adverse reactions.
The European Medicines Agency (EMEA) concluded that the moxifloxacin safety assessment concluded that the use of moxifloxacin-containing drugs should be restricted in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis and community access. In the case of pneumonia, moxifloxacin can only be used if other antibacterials are not available or the treatment is ineffective. EMEA also recommends warnings to strengthen moxifloxacin oral preparations.
Moxifloxacin is a fluoroquinolone antibacterial agent. Its oral preparation has been approved in accordance with the approval procedures of EU member states. It has been on the market for nearly 10 years and is used to treat acute bacterial sinusitis, acute exacerbation of chronic bronchitis and community-acquired pneumonia. Some member states also use moxifloxacin for the treatment of mild to moderate pelvic inflammatory disease.